Literature DB >> 19854535

Alternating 2'-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist.

Svetlana Hamm1, Eicke Latz, Doris Hangel, Thomas Müller, Philipp Yu, Douglas Golenbock, Tim Sparwasser, Hermann Wagner, Stefan Bauer.   

Abstract

Small interfering RNA (siRNA) is widely used to modulate gene expression, but its potential induction of cytokines via Toll-like receptors (TLR) strongly impairs its use. Selective 2'-O-ribose methylation of sense or antisense strand can abolish the immunostimulatory potential, however, no universal approach is available and the mechanism of action is unknown. Here, we demonstrate that alternating 2'-O-ribose methylation of the sense strand within a siRNA duplex specific for eGFP or beta(2)-microglobulin destroyed its immunostimulatory function in primary immune cells, while reduction in target gene expression was functional. Furthermore, addition of siRNA containing a 2'-O-ribose-methylated sense strand to immunostimulatory siRNA abolished its stimulatory activity and binding studies revealed that 2'-O-ribose-methylated RNA bound stronger to TLR7 than unmodified RNA. We conclude that 2'-O-ribose methylation acts as inhibitor for RNA-driven immune stimulation via TLR7 and recommend alternating 2'-O-ribose methylation of the sense strand as a universal approach for the generation of non-immunostimulatory siRNA. Copyright 2009 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19854535     DOI: 10.1016/j.imbio.2009.09.003

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  37 in total

1.  Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.

Authors:  Nikunj M Shukla; Subbalakshmi S Malladi; Victor Day; Sunil A David
Journal:  Bioorg Med Chem       Date:  2011-05-01       Impact factor: 3.641

Review 2.  Chemical modification of siRNA bases to probe and enhance RNA interference.

Authors:  Hayden Peacock; Arunkumar Kannan; Peter A Beal; Cynthia J Burrows
Journal:  J Org Chem       Date:  2011-08-17       Impact factor: 4.354

3.  Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.

Authors:  Timothy Pepini; Anne-Marie Pulichino; Thomas Carsillo; Alicia L Carlson; Farid Sari-Sarraf; Katrin Ramsauer; Jason C Debasitis; Giulietta Maruggi; Gillis R Otten; Andrew J Geall; Dong Yu; Jeffrey B Ulmer; Carlo Iavarone
Journal:  J Immunol       Date:  2017-04-17       Impact factor: 5.422

4.  A ribonucleoprotein octamer for targeted siRNA delivery.

Authors:  Wanyi Tai; Junwei Li; Eva Corey; Xiaohu Gao
Journal:  Nat Biomed Eng       Date:  2018-07-12       Impact factor: 25.671

5.  Nucleobase and ribose modifications control immunostimulation by a microRNA-122-mimetic RNA.

Authors:  Hayden Peacock; Raymond V Fucini; Prasanna Jayalath; José M Ibarra-Soza; Henry J Haringsma; W Michael Flanagan; Aarron Willingham; Peter A Beal
Journal:  J Am Chem Soc       Date:  2011-06-01       Impact factor: 15.419

6.  The application of RNAi-based treatments for inflammatory bowel disease.

Authors:  Morten Tobias Jarlstad Olesen; Borja Ballarín-González; Kenneth Alan Howard
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

Review 7.  MicroRNA replacement therapy for cancer.

Authors:  Jon C Henry; Ana Clara P Azevedo-Pouly; Thomas D Schmittgen
Journal:  Pharm Res       Date:  2011-08-31       Impact factor: 4.200

8.  Preclinical Safety Assessment of Therapeutic Oligonucleotides.

Authors:  Patrik Andersson
Journal:  Methods Mol Biol       Date:  2022

Review 9.  Antisense oligonucleotides: the next frontier for treatment of neurological disorders.

Authors:  Carlo Rinaldi; Matthew J A Wood
Journal:  Nat Rev Neurol       Date:  2017-12-01       Impact factor: 42.937

Review 10.  Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology.

Authors:  Lígia Catarina Gomes-da-Silva; Sérgio Simões; João Nuno Moreira
Journal:  Cell Mol Life Sci       Date:  2013-11-13       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.